In search of the optimal proteosome inhibitor. How, when and for whom?

[1]  G. Morgan,et al.  Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive) , 2021, Haematologica.

[2]  G. Morgan,et al.  Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. , 2021, PLoS medicine.

[3]  M. Boccadoro,et al.  Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial , 2020 .

[4]  S. Lonial,et al.  Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.

[5]  M. Dimopoulos,et al.  Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials , 2020, Cancer medicine.

[6]  P. Galieni,et al.  Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies , 2020, Haematologica.

[7]  M. Dimopoulos,et al.  Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. , 2019, Blood.

[8]  A. Palumbo,et al.  Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma , 2018, Leukemia.

[9]  H. Goldschmidt,et al.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  H. Einsele,et al.  Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial , 2017, British journal of haematology.

[11]  A. Dispenzieri,et al.  Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma , 2016, Leukemia.